BioSpace News Archive

TRxADE HEALTH, INC., a parent company of pharmaceutical business-to-business exchange platform, which recently merged with Superlatus, Inc., reconfirms its commitment to pharmaceutical marketplace via its subsidiary Trxade, Inc. and is pleased to clarify its commitment to the pharmaceutical industry.

NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”) today presented a poster with interim Phase I trial data on the use of its investigational NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the XXVI World Congress of Neurology (WCN) Annual Meeting in Montreal, QC, Canada and online.

Rezolute, Inc. announced that the European Medicines Agency has granted Priority Medicines eligibility to RZ358 for the treatment of congenital hyperinsulinism.

89bio, Inc. announced that the Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference being held on Tuesday, October 24, 2023.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced results of a pre-clinical study on its CRB-913 cannabinoid type-1 receptor (CB1) inverse agonist have been selected for oral presentation at the 11th annual Obesity Journal Symposium, held during the 2023 Obesity Week Conference in Dallas, Texas October 14-17, 2023.

ProPhase Labs, Inc., a next generation biotech, genomics, therapeutics and diagnostics company, unveiled the substantial expansion strategy for its wholly-owned subsidiary, Pharmaloz Manufacturing, Inc.

Ocean Biomedical, Inc. (NASDAQ:OCEA) today announced that its joint venture partner, Virion Therapeutics, LLC, is now enrolling patients in its Phase 1b study for a first-in-class treatment of chronic Hepatitis B (Clinicaltrials.gov #NCT06070051) in Hong Kong and New Zealand, with additional sites in the United States to become active later this year.

Flamingo Therapeutics announced the presentation of a “Trials-in-Progress”, or TiP, poster at the ESMO Congress 2023, taking place October 20-24, 2023, in Madrid, Spain.

ImmunoForge today announced that it has dosed the first patient in its Phase 2 clinical trial to evaluate the efficacy, safety, and pharmacokinetic properties of Froniglutide in patients with dermatomyositis/polymyositis.

BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced a new partnership with GenomeFrontier Therapeutics AU Pty Ltd., the Australian entity of GenomeFrontier Therapeutics Inc. headquartered in Taiwan, for a project involving development of innovative virus-free chimeric antigen receptor T cell products (CAR-T) for cancer treatment.